[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69014137D1 - Immunogenische Zusammensetzungen gegen Gastrin-Peptide. - Google Patents

Immunogenische Zusammensetzungen gegen Gastrin-Peptide.

Info

Publication number
DE69014137D1
DE69014137D1 DE69014137T DE69014137T DE69014137D1 DE 69014137 D1 DE69014137 D1 DE 69014137D1 DE 69014137 T DE69014137 T DE 69014137T DE 69014137 T DE69014137 T DE 69014137T DE 69014137 D1 DE69014137 D1 DE 69014137D1
Authority
DE
Germany
Prior art keywords
immunogenic compositions
disclosed
compositions against
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69014137T
Other languages
English (en)
Other versions
DE69014137T2 (de
Inventor
Philip C Gevas
Stephen Grimes
Stephen L Karr
Richard L Littenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptor Biologix Inc
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/301,353 external-priority patent/US5023077A/en
Application filed by Aphton Corp filed Critical Aphton Corp
Publication of DE69014137D1 publication Critical patent/DE69014137D1/de
Application granted granted Critical
Publication of DE69014137T2 publication Critical patent/DE69014137T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69014137T 1989-01-24 1990-01-17 Immunogenische Zusammensetzungen gegen Gastrin-Peptide. Expired - Fee Related DE69014137T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,353 US5023077A (en) 1989-01-24 1989-01-24 Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US35119389A 1989-05-12 1989-05-12

Publications (2)

Publication Number Publication Date
DE69014137D1 true DE69014137D1 (de) 1994-12-22
DE69014137T2 DE69014137T2 (de) 1995-06-08

Family

ID=26972322

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69014137T Expired - Fee Related DE69014137T2 (de) 1989-01-24 1990-01-17 Immunogenische Zusammensetzungen gegen Gastrin-Peptide.

Country Status (12)

Country Link
US (3) US5607676A (de)
EP (1) EP0380230B1 (de)
JP (1) JP2526418B2 (de)
AT (1) ATE114160T1 (de)
AU (1) AU645967B2 (de)
CA (1) CA2045594C (de)
DE (1) DE69014137T2 (de)
DK (1) DK0380230T3 (de)
ES (1) ES2063912T3 (de)
IE (1) IE66267B1 (de)
PT (1) PT92938B (de)
WO (1) WO1990008774A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0380230B1 (de) * 1989-01-24 1994-11-17 Aphton Corporation Immunogenische Zusammensetzungen gegen Gastrin-Peptide
US6861510B1 (en) * 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
JP2000504692A (ja) * 1996-02-08 2000-04-18 アフトン・コーポレーション 胃腸癌治療用の免疫学的方法
US6072086A (en) * 1996-04-12 2000-06-06 Intergen Company Method and composition for controlling formaldehyde fixation by delayed quenching
IL132546A0 (en) * 1997-04-23 2001-03-19 Univ Michigan Bradykinin analogs as selective inhibitors of cell activation
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
DE69827621T9 (de) * 1997-05-12 2007-06-06 Aphton Corp., Woodland Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
EP1839673A3 (de) * 1998-05-15 2007-11-07 Receptor Biologix, Inc. Vorbeugung und Behandlung von Hypergastrinämie
EP1076561B1 (de) * 1998-05-15 2005-03-30 Aphton Corporation Kombinationstherapie zur behandlung von tumoren
EP1579863A3 (de) * 1998-05-15 2008-03-19 Receptor Biologix, Inc. Kombinationstherapie mit Anti-G17 Gastrin Antikörper zur Behandlung von Tumoren
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
CA2332774A1 (en) * 1998-05-15 1999-11-25 Dov Michaeli Method for the treatment of gastroesophageal reflux disease
ES2286883T3 (es) * 1998-05-15 2007-12-01 Receptor Biologix, Inc. Prevencion y tratamiento de la hipergastrinemia.
JP2003522105A (ja) * 1998-06-18 2003-07-22 チョワース、ミッチャル、ワイ. ヘリコバクター・ピロリ(Helicobacterpylori)関連疾患治療用医薬組成物
EP1372717A2 (de) * 2001-03-23 2004-01-02 Aphton Corporation Kombinationsbehandlung von pankreaskrebs
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
AU2003283004A1 (en) * 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
US20080096824A1 (en) * 2003-02-28 2008-04-24 Shigemi Matsuyama Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells
JP4689597B2 (ja) 2003-03-28 2011-05-25 レセプター バイオロジックス インク. ガストリンホルモン免疫アッセイ
CN1997669A (zh) * 2004-03-29 2007-07-11 受体生物技术公司 抗胃泌素激素单克隆抗体
EP1730193A2 (de) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoklonale antikörper gegen gastrinhormon
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
GB201121571D0 (en) * 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
CN109806387B (zh) 2012-07-13 2022-03-04 S-目标疗法有限公司 免疫调节疫苗
AU2014270595B2 (en) * 2013-05-21 2019-04-04 Tyg Oncology Ltd. Gastrin peptide immunogenic composition
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932242A (en) * 1957-11-21 1976-01-13 Bartley Charles E Solid propellant with butyl rubber binder
DE2256445C3 (de) * 1972-11-17 1981-11-05 Hoechst Ag, 6000 Frankfurt Heptapeptide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
SU1414392A1 (ru) * 1982-12-29 1988-08-07 Всесоюзный кардиологический научный центр АМН СССР Противо звенное средство
FR2575164B1 (fr) * 1984-12-20 1987-03-20 Sanofi Sa Esters de tri- et tetrapeptides inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
EP0380230B1 (de) * 1989-01-24 1994-11-17 Aphton Corporation Immunogenische Zusammensetzungen gegen Gastrin-Peptide
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17

Also Published As

Publication number Publication date
JPH04503072A (ja) 1992-06-04
CA2045594C (en) 2002-08-13
US5609870A (en) 1997-03-11
AU645967B2 (en) 1994-02-03
DE69014137T2 (de) 1995-06-08
CA2045594A1 (en) 1990-07-25
ATE114160T1 (de) 1994-12-15
IE900250L (en) 1990-07-24
US5785970A (en) 1998-07-28
WO1990008774A1 (en) 1990-08-09
IE66267B1 (en) 1995-12-27
PT92938B (pt) 1996-09-30
JP2526418B2 (ja) 1996-08-21
EP0380230B1 (de) 1994-11-17
PT92938A (pt) 1990-07-31
AU5082090A (en) 1990-08-24
EP0380230A2 (de) 1990-08-01
ES2063912T3 (es) 1995-01-16
DK0380230T3 (da) 1995-01-16
EP0380230A3 (de) 1991-06-26
US5607676A (en) 1997-03-04

Similar Documents

Publication Publication Date Title
ATE114160T1 (de) Immunogenische zusammensetzungen gegen gastrin- peptide.
RU93048636A (ru) 7-/замещенные/-8-/замещенные/-9-/замещенные амино/-6-диметил-6-дезокситетрациклины, промежуточные соединения, способы получения соединений, способ профилактики и лечения и фармацевтическая композиция
ATE60697T1 (de) Verfahren zur bekaempfung von pilzen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
DE69432513D1 (de) Gangliosid-klh-konjugatimastoffe mit qs-21
DE69303803D1 (de) Behandlungsmethode zur Bodenverfestigung
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
DE69330899D1 (de) Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE3873846D1 (de) Behandlungsapparat und verfahren.
NO880292L (no) Fremgangsmaate for behandling av humle.
BR9007738A (pt) Metodo de tratamento de couros
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE3878137D1 (de) Behandlungsmethode zur bodenstabilisierung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: JABBUSCH, ARENDT & SIEKMAN, 30161 HANNOVER

8327 Change in the person/name/address of the patent owner

Owner name: RECEPTOR BIOLOGIX, INC. (N.D.GES.D. STAATES DE, US

8339 Ceased/non-payment of the annual fee